TEL AVIV, Israel, November 30, 2015 /PRNewswire/ --
Elbit Imaging Ltd. (TASE, NASDAQ:
EMITF) ("Elbit" or the "Company") announced today
that it was informed by InSightec Ltd. ("InSightec"),
that the Korean Ministry of Food and Drug Safety (MFDS) has
approved its Exablate Neuro system to treat movement, pain and
behavioral disorders.
Insightec's Exablate Neuro platform is transforming medicine by
presenting a non-invasive treatment alternative that combines two
technologies: Focused Ultrasound, which is used to lesion the
targeted tissue deep in the brain, and Magnetic Resonance Imaging
(MRI), which is used to guide the ultrasound waves to the specific
target tissue and provide real-time feedback on treatment progress
and outcome. The result of the above integration is a breakthrough
therapy platform that enables outpatient procedures.
This regulatory approval allows Korean patients suffering from
neurological disorders which cause significant disability access to
a new, non-invasive treatment option that does not require open
surgery. Previous treatment options for patients who do not respond
to drugs include deep brain stimulation, radiofrequency ablation
and radiosurgery which are highly invasive and/or involve risks
such as ionizing radiation, infection, bleeding and collateral
brain tissue damage.
The Company holds approximately 89.9% of the share capital of
Elbit Medical Technologies Ltd. (TASE: EMTC-M) (on a fully diluted
basis) which, in turn, holds approximately 29.6% of the share
capital in InSightec (on a fully diluted basis).
About Elbit Imaging Ltd.
Elbit Imaging Ltd. operates in the following principal fields of
business: (i) Commercial centers - initiation, construction, and
sale of commercial centers and other mixed-use property projects,
predominantly in the retail sector, located in Central and
Eastern Europe. In certain
circumstances and depending on market conditions, the Group
operates and manages commercial centers prior to their sale. (ii)
Hotels - hotels operation and management. (iii) Medical
industries and devices - (a) research and development, production
and marketing of magnetic resonance imaging guided focused
ultrasound treatment equipment, and (b) development of stem cell
population expansion technologies and stem cell therapy products
for transplantation and regenerative medicine. (iv) Residential
projects - initiation, construction and sale of residential units
or plots designated for residential located primarily in
India.
Safe Harbor Statement under the Private Securities Litigation
Reform Act of 1995
Any forward-looking statements in our releases include
statements regarding the intent, belief or current expectations of
Elbit Imaging Ltd. and our management about our business, financial
condition, results of operations, and its relationship with its
employees and the condition of our properties. Words such as
"believe," "would,"
"expect," "intend,"
"estimate" and similar expressions are
intended to identify forward-looking statements but are not
the exclusive means of identifying such statements. Actual results
may differ materially from those projected, expressed or implied in
the forward-looking statements as a result of various factors
including, without limitation, the factors set forth
in our filings with the Securities and Exchange Commission
including, without limitation, Item 3.D of our annual report on
Form 20-F for the fiscal year ended December
31, 2014, under the caption
"Risk Factors." Any forward-looking
statements contained in our releases speak only as of the date of
such release, and we caution existing and prospective investors not
to place undue reliance on such statements. Such forward-looking
statements do not purport to be predictions of future events or
circumstances, and therefore, there can be no assurance that any
forward-looking statement contained our releases will prove to be
accurate. We undertake no obligation to update or revise any
forward-looking statements.
For Further Information:
Company Contact
Ron Hadassi
Chairman of the Board of Directors
Tel: +972-3-608-6048
Fax: +972-3-608-6050
ron@elbitimaging.com
SOURCE Elbit Imaging Ltd.